Introduction {#S1}
============

[@B70] found a transcription factor (TF), which can be bound specifically to the promoter of selenocysteine tRNA in *Xenopus* oocytes and named it Staf (selenocysteine tRNA gene transcription activating factor). In the same year, [@B77] reported zinc finger protein 143 (ZNF143), a human homolog of the transcriptional activator Staf, was located on the human 11th chromosome, 11p15.3--15.4. Subsequently, [@B1] isolated and characterized m*-*Staf from mouse mammary gland, which is consistent with human ZNF143. ZNF143 is a member of the Kruppel family and is a widely expressed transcriptional activation factor that regulates gene expression associated with cell cycle and DNA replication ([@B31]). Therefore, it is widely involved in a variety of cellular and pathogenic processes, such as cell survival, growth, proliferation, etc. ([Table 1](#T1){ref-type="table"}). However, the molecular mechanism of ZNF143 in regulating gene expression remains elusive.

###### 

The role of ZNF143 in cancer progression.

  ZNF143 status           Cancer type                                    Association                                                             References
  ----------------------- ---------------------------------------------- ----------------------------------------------------------------------- ------------
  Knockdown               Human prostate cancer PC3                      Induce cell apoptosis                                                   [@B31]
                          Breast carcinoma                               Increase cellular motility                                              [@B55]
                          Colon cancer (HCT116)                          Increase cell migration and invasion                                    [@B54]
                          HeLa-S3                                        Reduce cell proliferation                                               [@B50]
                          Breast cancer                                  Better cell survival                                                    [@B56]
                          HeLa                                           Reduce cell proliferation, cell-cycle progression, and cell viability   [@B59]
                          Colon cancer                                   Increase cell plasticity                                                [@B79]
  Overexpression          PC3 prostate cancer cell lines                 Increase cell division                                                  [@B32]
                          Gastric cancer(GC)                             Enhance GC migration                                                    [@B83]
                          HepG2 and HeLa                                 Increase cell survival and differentiation                              [@B21]
  Positively expression   Lung cancer                                    Increase cell growth                                                    [@B33]
                          Lung adenocarcinoma                            With highly invasive and proliferation                                  [@B33]
                          Ovarian tumors and Low-grade ovarian cancers   Relate to cancer invasion, metastasis formation                         [@B61]

In recent years, studies have revealed that ZNF143 not only exists in most cancer cells but is also necessary for the normal development of tissues ([@B32]; [@B24]; [@B33]; [@B54]; [@B83]; [@B55]). Genome-wide analyses have shown that TF ZNF143 with sequence binding specificity is usually bound to the promoter of its regulatory gene and promotes the formation of chromatin loop by interacting with other chromatin structure and organization factors, such as CCCTC-binding factor (CTCF) and cohesin ([@B25]; [@B3]; [@B89]; [@B88]; [@B43]; [@B84]). In summary, as a key TF, ZNF143 plays a critical role in chromatin loop formation and gene regulation ([Table 2](#T2){ref-type="table"}), illustrating great importance in the study of its regulatory mechanism.

###### 

ZNF143 plays a critical role in chromatin interaction.

  Cell type                                           Detection method                                                Interaction factor               References
  --------------------------------------------------- --------------------------------------------------------------- -------------------------------- ----------------
  GM12878, K562, HelaS3                               Carbon-copy chromatin conformation capture (5C), 3C, ChIP-seq   Cohesin (SMC3), CTCF             [@B3]
  GM12878, K562                                       ChIA-PET, ChIP-seq, RNA-seq                                     Cohesin (RAD21), CTCF            [@B25]
  GM12878, K562                                       ChIA-PET, ChIP-seq                                              Cohesin (RAD21 and SMC3), CTCF   [@B89]
  Kc167, GM12878                                      Hi-C, ChIP-seq                                                  Cohesin (RAD21), CTCF            [@B43]
  HEK293T                                             Hi-C                                                            Cohesin (RAD21), CTCF            [@B84]
  HeLa-S3, HEK293, K562, HPB-ALL, NIH3T3, mESC, MEF   ChIP-Seq, RNA-seq                                               Notch1, THAP11                   [@B50]
  293T/17, HeLa, SW620, T98G                          ChIP-Seq                                                        THAP11, HCF-1                    [@B59]; [@B80]
  Mouse ES                                            ChIP                                                            Oct4                             [@B8]
  Human TLL                                           RNA-microarray, ChIP-Seq                                        Notch1, RBPJ                     [@B82]
  HeLa                                                RNA-microarray, ChIP-Seq                                        HCF-1, THAP11, YY1, GABP         [@B41]

The Structural Features of ZNF143 {#S2}
=================================

The amino acid sequence of human ZNF143 is highly homologous to both m*-*Staf and Staf. Among its sequence, 97.1 and 84% residues are identical to those of m-Staf and Staf, respectively ([@B70]; [@B1]; [@B47]). Structurally, these proteins consist of three regions (A, B, and C) ([Figure 1](#F1){ref-type="fig"}). Analysis of the three regions indicates that the central region B (residues 220--428 in ZNF143 and m*-*Staf, residues 267--468 in Staf) encompasses seven tandemly repeated zinc fingers of the C2H2 type, is highly basic, while the regions A (residues 1--219 in ZNF143 and m*-*Staf, residues 1--266 in Staf) encodes four repeated motifs and C (residues 429--626 in ZNF143 and m*-*Staf, residues 469--600 in Staf) are acidic ([Figure 1](#F1){ref-type="fig"}). The central region of seven zinc fingers domain is the DNA binding domain. Outside of the central domain, N-domain (region A) is the activation domain both for mRNA and snRNA, and the characteristic features of this domain of these three proteins are very simlar. The function of C-domain (region C) is unclear ([@B47]). Strikingly, the four repeated motifs can be observed between residues 39 and 135 in region A of ZNF143/m-Staf (residues 84 and 176 in region A of Staf) ([Figure 1](#F1){ref-type="fig"}). Each repeat motif contains 15 amino acids and the distance between them contains 10--12 amino acids ([@B70]).

![Schematic representation of structural features of human ZNF143 in comparison with m-Staf and Staf. Three regions of these three proteins can be distinguished: A contains mRNA and snRNA activation domains with the presence of the four repeated motifs. B is the central seven zinc finger domain and is therefore a DNA binding domain. C is a region with unknown function.](fgene-11-00338-g001){#F1}

As a TF, it is noted that the tandemly repeated zinc finger domain (DNA binding domain) and the element of repeated motifs (activation domain) are especially well conserved among these three proteins ([@B47]). It is reported that this TF possesses the capacity to bind over 2000 promoter regions of both mRNA and small nuclear RNA (snRNA) genes ([@B47], [@B45]). Recently, [@B50] have found that ZNF143 has two main DNA binding motifs of high affinity, namely, SBS1(GTTATGGAATTCCCATTATGCACCGCG) and SBS2 (AAACTACAATTCCCATTATGCACCGCG). Both of them are closely related to its specific binding on the chromatin, and thus initiate gene expression and regulation.

The Function of ZNF143 {#S3}
======================

Regulating Cell-Cycle Progression {#S3.SS1}
---------------------------------

TF ZNF143 regulates gene expression associated with cell cycle. Many studies utilize knockdown or overexpression methods to evaluate the effect of ZNF143 on cancer cell progression. For example, [@B31] have reported that ZNF143 is associated with cell cycle and cell proliferation, whereas ZNF143 knockdown causes human prostate cancer PC3 cells to stagnate during G2/M and is accompanied with apoptosis. By establishing two forced expression of ZNF143 PC3 cancer cell lines, they found that overexpress genes strongly associated with cell cycle and cell division ([@B32]). ZNF143 knockdown induces increased breast cancer motility, which indicates that ZNF143 expression contributes to breast cancer progression ([@B55]). In addition, low ZNF143 expression exhibits better cell survival through an autophagic process by regulating the p53--Beclin1 axis in breast cancer cells ([@B56]). ZNF143 is essential and sufficient for Skp2 promoter activity and ZNF143 silencing inhibits cell proliferation; however, ectopic ZNF143 can rescue Skp2 expression ([@B26]). Overexpression of ZNF143 enhances transaldolase promoter activity in HepG2 and HeLa cells and ZNF143 plays a key role in controlling cell survival and differentiation ([@B21]). Simultaneously, other researchers have reported that THAP11/ZNF143/HCF-1 complex is an indispensable component of the transcriptional regulatory network and disruption of this complex leads to reduced cell proliferation, cell-cycle progression, and cell viability ([@B59]). [@B50] have also showed that ZNF143, ICN1, and THAP11 play a pivotal role in modulating cell proliferation of rapidly dividing cells. [@B46] have found that human BUB1B gene mediates the activity of spindle checkpoints to ensure chromosomal stability and euploidy, requires ZNF143 binding.

Regulating Embryonic Development and Maintaining Stem Cell Identity {#S3.SS2}
-------------------------------------------------------------------

As a key TF, ZNF143 has a critical function in regulating embryonic development. [@B24] have found that ZNF143 significantly changes zebrafish embryonic phenotypes. Therefore, ZNF143 is necessary for the normal development of zebrafish embryos. The identification and characterization of paralogous genes is also critical for understanding gene function. In the functional study of ZNF143, [@B29] have found that *znf143a*, a novel paralog of *znf143*, encodes a strong transcriptional activator protein and performs a similar role in the normal development of zebrafish embryos but expressed at a different level during early development. In mouse embryonic stem (ES) cells, ZNF143 regulates Nanog by regulating the binding of Oct4, and ZNF143 is also critical for maintaining human ES cell identity ([@B8]).

Potential Drug Design Target {#S3.SS3}
----------------------------

TF ZNF143 is a potential drug design target to treat solid cancers. After cisplatin treatment, the binding activity of ZNF143 and MRP S11 significantly increases. This indicates that ZNF143 is involved in response to DNA damage ([@B30]; [@B78]; [@B81]). P73 promotes ZNF143 binding with cisplatin-modified DNA, indicating that ZNF143 can regulate the transcription of DNA repair genes ([@B81]). ZNF143 can also mediate cell survival by upregulating glutathione peroxidase (GPX1) activity. Thus, ZNF143 interference can increase drug sensitivity to cisplatin treatment of mitochondrial dysfunction ([@B38]). GAIP-interacting protein, C-terminus (GIPC) induces ZNF143 expression by participating in IGF-1 signal transduction to regulate reactive oxygen products ([@B57]). ZNF143 is also involved in the migration and invasion of colon cancer cells through a ZEB1-E- cadherin-linked pathway ([@B54]). The expression levels of ZNF143 and IL-8 are inversely correlated with three-dimensionally grown spheroids and colon cancer tissues ([@B79]). ZNF143 is accompanied with an increase in MIB-1 index in patients with lung adenocarcinoma, leading to high cell proliferation activity and poor prognostic treatment ([@B33]). [@B83] have found that ZNF143 expression can enhance the metastasis of gastric cancer cells, indicating that ZNF143 can be a drug target for the treatment of gastric cancer. The reduction in ZNF143 expression eventually leads to the cobaltamine transport protein not effectively transporting cobalamin ([@B60]). The expression patterns of ZNF143 and ZNF281 in serous borderline ovarian tumors (SBOTs) and low-grade epithelial ovarian carcinomas (EOCs) play a key role in cancer invasion, metastasis formation, and chemotherapy resistance ([@B61]). ZNF143 is an upstream regulator to increase the expression of the RNA binding protein TARBP2 in breast and lung cancers ([@B12]). Thus, how to effectively design small molecule drugs to target ZNF143 is imminent. Fortunately, [@B22] have found that new small molecules YPC-21661 and YPC-22026 can reduce the expression of their target genes RAD51, PLK1, and Survivin by inhibiting the binding of ZNF143 to their promoters. In the future, it is believed that more and more molecule drugs will be exploited by targeting ZNF143 to treat related cancers.

ZNF143 Regulates Gene Expression and Its Mechanism {#S4}
==================================================

ZNF143 Participates in the Regulation of Coding and Non-coding Genes {#S4.SS1}
--------------------------------------------------------------------

As an important TF, ZNF143 regulates the expression of various genes. During transcription activation, [@B69] have found that ZNF143 activation domains bound by mRNA and snRNA are different. [@B47] first have found ZNF143 can activate the transcription from RNA polymerase II TATA box-containing mRNA promoters. For example, [@B35] have reported that ZNF143 is the key TF upregulating the molecular chaperone coding gene Cctα transcription through binding with the two activation elements (CAE1 and CAE2). [@B39] have also showed that ZNF143 stimulates transcription of the human interferon regulatory factor-3 (IRF-3) gene by binding to *Sph*I postoctamer homology (SPH) elements *in vitro* and in transfected cells. ZNF143 plays an important role in the transcription of neuronal nitric-oxide synthase (nNOS) exon 1, the mutation of the binding site of ZNF143 leads to a significant reduction in the activity of this exon ([@B64]). [@B4] use ChIP as well as deletion/mutation analysis reveal that the aldehyde reductase is significantly enhanced by transcription activation after binding to ZNF143. [@B10] have found that ZNF143, together with CAAT factors, regulates human synaptobrevin-like 1 (SYP-like 1) through binding to the SYBL1 promoter in HeLa cells. [@B17] have reported that ZNF143 binds to the promoter of mitochondrial TF A (Tfam) to regulate transcription initiation and replication of mitochondrial DNA in consistent with Sp1, NRF-1, and NRF-2. ZNF143 binds with the −305/−107 of the BUB1B promoter to regulate BUB1B expression to maintain chromosomal stability and euploidy ([@B46]). [@B20] have reported that ZNF143, specifically binds to the 8-bp sequence (CCCAGCAG), ∼100 bases upstream of the C/EBPα transcription start site (TSS), plays an important role in the expression of C/EBPα in myeloid cells.

ZNF143 acts as a transcription-activated factor under the joint action of RNA polymerase III ([@B68]). The snRNA and snRNA-type genes require the binding of ZNF143 during transcription, such as human U4C, U6, Y4, 7SK; mouse U6 RNAs and *Xenopus* U1b1, U2, U5, MRP. However, the binding of ZNF143 to snRNA occurs on a distal sequence element (DSE) ([@B68]). By comparing ZNF143 recognition sequence of human U6 snRNA and selenocysteine tRNA, Schaub et al. have found that there are only 47% consistent in sequences. In the seven zinc fingers of ZNF143 recognition sequence, the first zinc finger is necessary for selenocysteine tRNA promoter identification, whereas U6 snRNA is not. The seventh zinc finger is essential for the binding activity of them. The flexibility binding results in differences in transcription activation mechanisms ([@B65]). U6 snRNA transcription activation requires ZNF143--DNA--Oct-1 complex, whereas selenocysteine tRNA requires ZNF143-DNA complex ([@B67]). [@B66] have found that zinc fingers 3--6 are the minimum zinc finger regions.

Self-Regulation of ZNF143 {#S4.SS2}
-------------------------

To maintain stable ZNF143 expression at normal levels, the transcription feedback regulation mechanism is the simplest and most direct means. ZNF143 selectively adjusts reverse expression by using a low affinity binding site (TSS2) located downstream of the TSS. When ZNF143 expression is higher than normal, transcripts containing longer 5′-UTR (few translation products) are produced by TSS2 transcription. In addition, when ZNF143 levels are lower than normal, the canonical TSS1 binding site is used to express transcripts containing shorter 5′-UTR (many translation products). This transcriptional auto-regulatory mechanism regulates ZNF143 expression by the conversion of the TSS switch, which plays an important role in cell proliferation and growth ([@B48]). Given that ZNF143 is closely related to many biological processes, its expression must be strictly regulated. Ngondo et al. have found that ZNF143 transcripts have three different lengths of 3′-UTR, with the longer 3′-UTR isoform containing variable polyadenylation sites, miRNA target sites, or AU-rich element (ARE). Thus, it tends to post-transcriptional regulation. The longest 3′-UTR isoform contains an unstabilizing ARE and is targeted by mir-590-3p. These results emphasize that ZNF143 post-transcriptional regulation depends on the long 3′-UTR isoform ([@B49]).

ZNF143 Is a Chromatin-Looping Factor {#S4.SS3}
------------------------------------

Myslinski et al. have predicted the whole genome binding sites of ZNF143 through computer simulation (*in silico*) and biochemical methods. They speculated that at least 2500 ZNF143-binding sites are distributed in 2000 promoter regions throughout the mammalian genome. Further research has found that the presence of ZNF143-binding site alone can initiate the expression of a luciferase reporter gene, suggesting that ZNF143 itself exhibits the ability to recruit the transcription machinery ([@B45]). Recently, Wang et al. have reported the co-localization of RBPJ/Notch1/ZNF143, in which ZNF143 can bind with 40% of the Notch1 sites, and RBPJ shows high promoter binding preference by embedding in the ZNF143 motifs. These results may indicate a dynamic exchange of RBPJ/Notch1 and ZNF143 complexes through competition in the binding sites ([@B82]). [@B50] have revealed that ZNF143, THAP11, and Notch1 regulate the common target genes through the mutually exclusive occupation of overlapping binding sites. [@B41] have found that HCF-1 is bound with 5400 CpG island promoters. HCF-1, ZNF143, and THAP11 exhibit co-localization, with HCF-1 in collaboration with ZNF143 and THAP11 plays an important role in the transcriptional regulation of HeLa cells. Parker et al. have found that HCF-1, as a coregulator of the TF E2F proteins, is not directly collected in the promoter region but is mediated by ZNF143 and THAP11. HCF-1/ZNF143/THAP11 as a complex that occupies specific sites of chromatin co-regulates the expression of cell proliferation genes ([@B59]). However, how DNA sequences guide the THAP11/ZNF143/HCF-1 complex to chromatin remains in dispute. [@B80] have explicitly proposed that ACTACA, as a joint submotif of ZNF143 and THAP11, guides THAP11 and HCF-1 to ZNF143-occupied loci and emphasized the importance of the position, spacing, and direction relative to the ZNF143 core motif.

TF ZNF143 can interact with other transcriptional regulators in mediating chromatin loop formation. Chromatin interactions between promoters and long-region regulatory elements can determine the expression level of a gene ([@B13]; [@B14]). In recent years, with the development of high-throughput sequencing and chromatin conformation capture technologies (3C, chromatin conformation capture; Hi-C, chromatin conformation capture using high throughput sequencing; ChIA-PET, chromatin interaction analysis by paired-end tag sequencing) ([@B9]; [@B16]; [@B36]), increasing evidence indicates that the interaction between genomic regulatory elements plays an important role in regulating gene expression. [@B25] have discovered that ZNF143 plays an important role in mediated distal chromatin interactions. [@B3] have found that ZNF143, as a novel and key chromatin-looping factor, with sequence specificity dependency at promoters and links the distal regulatory elements together, playing an important role in the establishment of the genomic organization. ZNF143 binds to the PMM2 promoter could establish a functional chromatin loop enabling interaction between the promoter and distal regulatory elements, which allows specific spatiotemporal regulation of PMM2 ([@B7]). ZNF143 knockdown mainly eliminates or destabilizes chromatin loops ([@B84]). We also found that ZNF143 was involved in the CTCF-mediated chromatin interactions by cooperating with cohesin ([@B89]). Other researchers have showed that ZNF143 interactes with other regulators are also important for chromatin domain formation. For example, [@B42] have revealed that the formation of 3D chromatin domains is affected by positive driving factors CTCF, cohesin, ZNF143, polycomb proteins, and negative driving factors P300, RXRA, BCL11A, ELK1. CTCF binding sites are not only closely associated with topologically associating domain (TAD) boundaries, but also interact with ZNF143 and Yin Yang (YY)1 ([@B27]).

Conclusion and Prospects {#S5}
========================

ZNF143 can bind with multi-species, multi-type coding and non-coding genes ([@B70]; [@B68]; [@B47]). However, ZNF143 binding and co-initiative transcription differs due to the diversity of promoter structures. Although the promoter structure of H1 RNA, the RNA component of the human nuclear RNase P, is similar to that of vertebrate snRNA, H1 RNA's promoter is distributed within 100 bp of the 5′ flanking sequence and presents a highly compact structure to initiate transcription ([@B44]). ZNF143 binding with U6 found in zebrafish are located upstream of the TATA box and downstream of proximal sequence element (PSE), unlike the U6 of other species ([@B23]). The promoter of SCARNA2 is contained within 161 bp upstream of TSS due to its special transcription (different from SCARNA), whereas ZNF143 is the basic regulator ([@B18]).

As a general TF, ZNF143 participates in numerous cellular biological activities. Using comparative genomic analysis to identify the distribution of ZNF143 target genes, [@B45] have found that DNA binding and TFs account for 23%, protein synthesis/degradation/modification account for 21%, and DNA replication/cell cycle/cell growth/differentiation/apoptosis account for 13%. Anno et al. have also found that ZNF143 *per se* exhibits an inherently bidirectional transcription activity. Thus, ZNF143 has the ability to control the expression of divergent protein--protein and protein--non-coding RNA gene pairs ([@B2]). ZNF143 is expressed differently in various tissues. It is highly expressed in the lung, ovary and thymus, but weakly expressed in the brain, liver, and kidney ([@B21]). ZNF143 is highly expressed in many solid tumors, and it is involved in cisplatin resistance because cisplatin induced ZNF143 binds to cisplatin-modified DNA ([@B81]; [@B57]; [@B38]). Thus, novel small molecules can be designed for ZNF143 to enhance the sensitivity of cisplatin chemotherapy ([@B22]). ZNF143 is not only indispensable for the embryonic development of zebrafish but also necessary for ES cell identity and self-renewal capability of ES cell ([@B8]; [@B24]). What is more, histone methylation in the ZNF143 binding sites is usually related to transcription regulation. [@B87] have found that both active (H3K4me1, H3K4me3, and H3K27ac) and suppressive (H3K27me3) histone marks can modulate ZNF143 binding, which in turn, regulate gene expression. However, how to develop new and convenient detection systems to study the function of ZNF143 is still a big challenge. Recently, [@B63] have developed an improved auxin-inducible degron system to study TF function. After rapidly depleting the ZNF143 TF, transcriptional profiling indicates that ZNF143 activates transcription in cis and regulates promoter-proximal paused RNA polymerase density.

CTCF, cohesion, and ZNF143 are three major regulators involved in the establishment and maintenance of long-range chromatin interactions. In mammalian cells, TAD-free analysis indicates that the blocking effects of CTCF, cohesin, and ZNF143 depend on the distance between loci because each protein may participate at different scales of chromatin organization ([@B43]). CTCF and cohesin are the key factors in organizing the mammalian genome to form TADs and loops, and the CTCF loops are formed as a result of cohesin-dependent loop extrusion ([@B11]; [@B51]; [@B62]; [@B15]; [@B19]; [@B6]; [@B52]). ZNF143 is not only involved in CTCF/cohesin-mediated chromatin interactions, but also can bind directly to the promoter and connect it to distal regulatory elements (such as enhancer) to form chromatin loops ([@B25]; [@B3]; [@B89]). The recurrent C→T conversion at the ZNF143 locus influences the chromatin loop formation and alters distal gene expression in breast cancer ([@B86]). [@B37] have reported a new epigenetic feature called sparse conserved under-methylated CpGs (scUMCs) is involved in cell-specific regulation of long-range chromatin interaction mediated by chromatin-looping factors (CTCF, cohesin, and ZNF143), providing a new direction in the research of the relationship between DNA methylation and chromatin organization. Recent technical developments allow more accurately identify where TFs bind to DNA. Skene et al. have showed that their new *in situ* methods, such as cleavage under targets and release using nuclease (CUT&RUN) and cleavage under targets and tagmentation (CUT&Tag), will be viewed as a cost-effective and versatile alternative to ChIP because of low backgrounds, which requiring only ∼1/10th the sequencing depth as ChIP ([@B74]; [@B73]; [@B34]; [@B40]). Based on these methods, [@B72] have developed cleavage under tethered nuclease for conformational capture (Cut-C) technology to identify chromatin interactions mediated by a protein of interest along with the genome-wide distribution of the target proteins. Thus, using these latest technologies, we may be clearly captured the accuracy of chromatin loops mediated by ZNF143 in a genome-wide scale.

During mitosis, transcription is globally shut down, chromatin condenses, the nuclear envelope is disassembled, and most TFs are stripped off the mitotic chromosomes. How do the new daughter cells faithfully re-establish the cell-type specific transcription program? Recent discoveries that a select set of TFs remain associated with mitotic chromosomes suggest a phenomenon termed mitotic bookmarking ([@B28]). For example, many studies have reported that CTCF is still partially retained in mitotic chromosomes and chromatin structure dynamics during the mitosis-to-G1 phase transition ([@B5]; [@B85]; [@B71]; [@B76]; [@B53]; [@B58]; [@B91]). Thus, the presence of CTCF during mitosis may function as candidate mitotic bookmarking protein. This mechanism plays a potential and critical role in maintaining cell identity and cell destiny. Meanwhile, ZNF143 can interact with CTCF and mediate the formation of the chromatin loops. We recently discovered that ZNF143 was still partially bound to the chromosome during mitosis and 80% of the retained regions preferentially localized to promoters, supporting that it functioned mainly through promoters ([@B90]). Thus, the presence of CTCF and ZNF143 during mitosis may be crucial to recruit other regulatory factors to bind to chromosomes and re-establish chromatin loops in early G1 phase ([Figure 2](#F2){ref-type="fig"}). Therefore, further studies on ZNF143 are necessary to help reveal its regulatory mechanism during the cell cycle.

![Schematic representation of chromatin loop formation mediated by ZNF143, CTCF, cohesin, and other TFs during the cell cycle. ZNF143 is a potential mitotic bookmarking factor helps to re-establish chromatin loops in early G1.](fgene-11-00338-g002){#F2}

As a key TF, the role of ZNF143 in cancer progression through transcriptional regulation of genes related to DNA replication and cell cycle ([@B31]). Furthermore, Song et al. have showed that miR-590-3p could negatively modulate the expression of ZNF143 via binding to the ZNF143 3′-UTR and ZNF143 can directly activate FAM224A expression through binding to its promoter, forming the A1CF-FAM224A-miR-590-3p-ZNF143 positive feedback loop. This loop plays a critical role in regulating the malignant progression of glioma cells, providing a novel molecular target for glioma therapy ([@B75]). In recent years, with the technology and bioinformatics analysis development, the molecular mechanism of ZNF143-mediated gene transcriptional regulation has been largely exploited. Chromatin looping between promoters and distal regulatory elements depends on DNA binding by ZNF143 and other partners. In the future, how to comprehensively analyze the mechanism of ZNF143 in mediating gene expression of different cell types and discover the novel and potential functions of ZNF143 remains a considerable challenge.
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